Answers are grounded in this paper and cite their sources.
Reviews fenofibrate pharmacology and evaluates ABT-335 with statins in mixed dyslipidaemia, highlighting potential cardiovascular risk reduction.
BACKGROUND: Fenofibrate is the most widely used fibrate. Its efficacy and tolerability in the treatment of hypertriglyceridaemia and combined hyperlipidaemia have been demonstrated in several clinical trials. OBJECTIVE: To review the pharmacology, lipid-lowering and extra-lipid effects of fenofibrate and to preview ABT-335, an investigational new fenofibric acid molecule. RESULTS: The effects of fenofibrate are mediated through the active metabolite fenofibric acid, and are described in detail in the paper. ABT-335 is a salt of fenofibric acid and, unlike fenofibrate, does not require first pass metabolism to the active moiety. ABT-335 is being developed for combination use with statins, and has recently completed three large Phase III randomised controlled trials in which the efficacy and safety of ABT-335 in combination with the three most commonly prescribed statins, atorvastatin, simvastatin and rosuvastatin, was evaluated in patients with mixed dyslipidaemia. CONCLUSION: ABT-335 in combination with statins may provide a safe and efficacious treatment modality that enables achievement of several therapeutic goals in patients with mixed dyslipidaemia who have high cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Filippatos et al. (2008) conducted a review in Hyperlipidaemia / mixed dyslipidaemia. Fenofibrate and ABT-335 (fenofibric acid) in combination with statins (atorvastatin, simvastatin, rosuvastatin) was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: